Compare OC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OC | NUVL |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.8B |
| IPO Year | 2006 | 2021 |
| Metric | OC | NUVL |
|---|---|---|
| Price | $143.97 | $123.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | ★ $145.27 | $134.75 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | $1,239.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $97.53 | $71.14 |
| 52 Week High | $159.91 | $123.99 |
| Indicator | OC | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 67.23 |
| Support Level | $115.22 | $98.56 |
| Resistance Level | $159.91 | N/A |
| Average True Range (ATR) | 6.44 | 0.14 |
| MACD | -0.72 | -0.73 |
| Stochastic Oscillator | 43.62 | 94.64 |
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.